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Although the use of cord blood transplantation (CBT) is increasing, the optimal methods for conditioning and
graft-versus-host disease (GVHD) prophylaxis remain to be established. Among previous reports, the Institute
of Medical Science, University of Tokyo (IMSUT) has reported remarkably favorable results of CBT for
hematologic malignancies as a single-institute experience. The aim of the present multicenter prospective
study was to assess the safety and efﬁcacy of CBT performed precisely according to IMSUT transplantation
procedures. Thirty-three adult patients with hematologic malignancies, such as acute leukemia, chronic
myelogenous leukemia, or myelodysplastic syndrome, either lacking an HLA-identical sibling/HLA-matched
unrelated donor or requiring urgent transplantation were enrolled. Conditioning consisted of total body
irradiation (12 Gy), cytarabine, and cyclophosphamide. Cyclosporine A and methotrexate were used for GVHD
prophylaxis. Diagnoses were acute leukemia in 26 patients, chronic myelogenous leukemia in 4, and mye-
lodysplastic syndrome in 3; 12 patients were in ﬁrst complete remission, and the others were in advanced
stages at the time of CBT. Thirty-one patients achieved engraftment, and the cumulative incidence of grade
II-IV acute GVHD was 45% (95% conﬁdence interval, 28%-62%). With a median follow-up of 46.2 months in 16
surviving patients, the 1-year cumulative incidence of nonrelapse mortality was 15% (95% conﬁdence interval,
5%-30%). Causes of nonrelapse mortality were infection (n ¼ 4) and graft failure (n ¼ 1). The overall and
disease-free survival rates were 51% (95% CI, 34%-68%) and 42% (95% CI, 26%-59%), respectively. These results
suggest that the IMSUT CBT procedures can safely provide a high disease-free survival rate in patients with
high-risk hematologic malignancies.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the most promising curative treatment for hema-
tologic malignancies. Several hematopoietic stem cell sour-
ces are now available, and the use of cord blood
transplantation (CBT) has been increasing dramatically [1].
However, the outcomes of CBT are not necessarily satisfac-
tory, because of the high nonrelapse mortality (NRM).
Conditioning and prophylaxis against graft-versus-host
disease (GVHD) used in CBT have varied signiﬁcantly
among previous studies, and the optimal approaches remain
to be established [2-6]. Among those studies, the outcomesedgments on page 490.
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Science, University of Tokyo (IMSUT) were notably favorable
and in fact were superior to the outcomes of allogeneic bone
marrow transplantation (BMT) or peripheral blood stem cell
transplantation (PBSCT) from related and unrelated donors
at the same institution [7,8].
The IMSUT transplantation procedures involve a myeloa-
blative conditioning regimen using total body irradiation
(TBI), cyclophosphamide (CY), and high-dose cytarabine.
Cytarabine is combined with granulocyte colony-stimulating
factor (G-CSF) for myeloid malignancies. In addition, cyclo-
sporine A is given over 10 hours with short-term metho-
trexate (MTX) for GVHD prophylaxis. To date, however, no
study has systematically assessed whether IMSUT’s favorable
results would be reproduced if CBT for hematologic malig-
nancy were performed precisely according to IMSUT’s
transplantation procedures. Accordingly, we designed and
performed a multi-institutional study to evaluate the safetyTransplantation.
Table 1
Patient and Transplant Characteristics (n ¼ 33)
Characteristic Value
Age, years, median (range) 37 (21-54)
Sex, males/females, n 21/12
Body weight, kg, median (range) 55.0 (39.1-97.0)
Diagnosis, n
AML 20
ALL 6
CML 4
MDS 3
Disease status, n
CR1 12
CR2, chronic phase 2 5
Not in CR, blast crisis 16
Conditioning, n
TBI þ cytarabine þ G-CSF þ CY 27
TBI þ cytarabine þ CY 5
TBI þ CY 1
Cord blood units
HLA disparity, n
4-antigen match 29
5-antigen match 3
6-antigen match 1
Nucleated cells per kg body weight, median (range) 2.66 (2.00-4.58)
GVHD prophylaxis with CsA þ short-term MTX, n 33
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by strictly following these procedures.
PATIENTS AND METHODS
This study is a multi-institutional prospective study of the Kanto Study
Group for Cell Therapy. The protocol was approved by the Institutional
Review Boards of the 9 participating institutions and registered at http://
clinicaltrials.gov (NCT00270881). No patients were enrolled from IMSUT.
Written informed consent was obtained from all patients in accordancewith
the Declaration of Helsinki.
Patient Eligibility and Cord Blood Unit Selection
Eligibility criteria for this study included (1) age 20-55 years; (2) diag-
nosis of acute myelogenous leukemia (AML), acute lymphoblastic leukemia
(ALL), chronic myelogenous leukemia (CML), or myelodysplastic syndrome
(MDS) suitable for allogeneic HSCT; (3) lack of an available 5/6 or fully HLA-
matched related donor; (4) either lack of an available fully 6/6 HLA-matched
unrelated donor or the need for immediate HSCT based on the features of
the disease as judged by the treating physician; (5) availability of a 6/6, 5/6,
or 4/6 serologically HLA-matched cord blood unit with a minimum of
2  107 total nucleated cells per kilogram of recipient body weight before
cryopreservation in the Japan Cord Blood Bank Network; (6) Eastern
Cooperative Oncology Group performance status of 0 or 1; (7) adequate
function of main organs, including the liver, kidneys, lungs, and heart; and
(8) lack of anti-HLA (class I and/or II) antibody. Patients with a previous
history of HSCT, active infection, or active central nervous system disease or
psychiatric disorders were excluded. This protocol was only for patients
receiving single-unit CBT. HLA disparity was determined based on the
antigen level of HLA-A, -B, and -DR loci speciﬁed by low- or high-resolution
techniques.
Conditioning Regimen
All patients received the same myeloablative conditioning as described
previously [7-9]. TBI 12 Gy was delivered in 4 or 6 fractions for 2 or 3 days
(days -8, -7, and -6 or days -7 and -6). After completion of TBI, cytarabine at
a dose of 2 or 3 g/m2 was administered i.v. over 2 hours every 12 hours for 2
consecutive days (days -5 and -4). All patients received steroid eye drops for
prophylaxis against keratoconjunctivitis due to cytarabine. For myeloid
malignancies (AML, MDS, and CML), recombinant human granulocyte
colony-stimulating factor (G-CSF; lenograstim) was given by continuous
infusion at a daily dose of 5 mg/kg, starting 12 hours before the ﬁrst dose of
cytarabine and continuing until the last dose of cytarabine. Then CY 60 mg/
kg was administered i.v. over 2 hours for 2 consecutive days (days -3 and -2).
Cytarabine could be omitted in exceptional cases based on factors in the
patient’s background, such as a history of allergic reaction. No patient
received antithymocyte globulin as part of the conditioning regimen.
Infusion of Cord Blood, GVHD Prophylaxis, and Supportive Care
Two days after the completion of CY administration (day 0), patients
received CBT. The cord blood graft was thawed and immediately infused
without washing. GVHD prophylaxis was provided with short-term meth-
otrexate (MTX; 15 mg/m2 on day 1, and 10 mg/m2 on days 3 and 6) and
cyclosporine A (CsA). Leucovorin was given i.v. to ameliorate its toxicity.
CsA was given i.v. over 10 hours starting on day -1. The CsA dose was
adjusted at the discretion of the physician only if the trough level of CsA
was <100 ng/mL or adverse events associated with CsA developed.
Each patient was isolated in a laminar air-ﬂow or high-efﬁciency
particulate air-ﬁltered room. The administration of lenograstim at a dose
of 5 mg/kg was started 1 day after CBT and continued until neutrophil
recovery was achieved. Prophylactic ﬂuoroquinolone and ﬂuconazole (200
mg/day) were given orally, starting 14 days before transplantation. For
Pneumocystis pneumonia prophylaxis, cotrimoxazole was given for 14
consecutive days before transplantation and recommenced on a schedule of
2-3 days per week after sustained hematopoietic recovery was conﬁrmed.
Oral acyclovir at a dose of 1000 mg/day was given from day -7 to day 35.
Cytomegalovirus (CMV) reactivation was routinely monitored by CMV
antigenemia assay or PCR soon after neutrophil recovery, which triggered
preemptive therapy with ganciclovir. Intravenous immunoglobulin was
given in patients with a serum immunoglobulin G level <500 mg/dL.
Assessment of Chimerism, Engraftment, and GVHD
The chimerism study was performed on whole bone marrow cells at 1
month, 2 months, and 3 months after CBT. Analyses were performed by
ﬂuorescein in situ hybridization for X and Y chromosomes or by micro-
satellite PCR as appropriate. The day of myeloid engraftment was deﬁned as
the ﬁrst day of 3 consecutive days when the absolute neutrophil count
exceeded 0.5109/L. The day of platelet engraftment was deﬁned as the daywhen the absolute platelet count exceeded 20  109/L without platelet
transfusion. Primary graft failurewas deﬁned as lack of myeloid engraftment
until day 42; secondary graft failure, as a persistent loss of myeloid
engraftment after having achieved engraftment. Both acute and chronic
GVHD were diagnosed and graded based on published criteria [10,11].
Statistical Analysis
The primary endpoint of this study was 1-year NRM, and secondary
endpoints were engraftment, acute and chronic GVHD, infectious compli-
cations, dayþ100 NRM, relapse rate, disease-free survival (DFS), and overall
survival (OS). Survival rates were calculated by the Kaplan-Meier method.
Probability of acute GVHD, disease relapse, and NRM were estimated on the
basis of cumulative incidence curves to accommodate the following
competing events: death without GVHD and second transplantation for
graft failure for acute GVHD, death for relapse, and relapse for NRM [12].
Comparisons were made using the log-rank test or Gray test as appropriate.
Multivariate analyses were performed using the Cox proportional hazards
model or the Fine and Gray proportional-hazards model as appropriate.
P < .05 was considered to indicate statistical signiﬁcance in all analyses.
RESULTS
Patient Characteristics
Thirty-three patients were enrolled and underwent CBT.
Patient and transplant characteristics are summarized in
Table 1. At the time of CBT, 12 patients with AML/ALL were in
the ﬁrst complete remission (CR1) and were deﬁned as
standard-risk patients. The remaining 19 patients had
AML/ALL in CR2 or CML in chronic phase 2 (n ¼ 3) or
AML/ALL not in remission, MDS with an excess of blasts, or
CML in blastic crisis (n ¼ 16), and were deﬁned as high-risk
patients. Three patients in CR1 had Philadelphia
chromosomeepositive ALL. All but 1 patient received TBI,
cytarabine, and CY with or without G-CSF as conditioning.
Engraftment and Chimerism
Myeloid engraftment was obtained at a median of 26 days
(range, 18-60 days) in 31 patients. Platelet engraftment was
obtained at a median of 44 days (range, 25-140 days) in 26
patients. Two patients experienced primary graft failure,
caused by graft rejection in 1 patient and early disease
progression in 1 patient. One case of secondary graft failure
occurred after hemophagocytic syndrome. In the 27 patients
who underwent chimerism analysis, full donor chimerism
Table 2
Infectious Complications
Infection Number
Bacterial (n ¼ 14)
Bacteremia 10
Enteritis 1
Meningitis 1
Pneumonia 1
Cholecystitis 1
Fungal (n ¼ 5)
Candidemia 1
Invasive aspergillosis 3
Pneumocystis pneumonia 1
Viral (n ¼ 28)
CMV infection 23
CMV disease 1
HHV-6 central nervous system disorder 1
Parainﬂuenza virus pneumonia 1
Encephalitis* 2
HHV-6 indicates human herpesvirus 6.
* Causative virus was not identiﬁed.
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Figure 1. Cumulative incidences of NRM (A) and relapse rate (B), and Kaplan-
Meier estimates of OS and DFS (C). “þ” indicates a censored patient.
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at 2 months in 2 patients, and at 3 months in 1 patient.
Acute and Chronic GVHD
Acute GVHD developed in 21 of 31 evaluable patients
with myeloid engraftment (grade I in 6 patients, grade II in
10, grade III in 3, and grade IV in 2). The cumulative incidence
of grade II-IV acute GVHD up to day þ100 post-
transplantationwas 46% (95% CI, 27.8%-61.5%). Among the 10
patients with grade II acute GVHD, 6 did not require systemic
glucocorticoid in addition to CSA for the treatment of acute
GVHD. Among the 27 patients who survived more than 100
days after transplantation, 6 patients developed chronic
GVHD (2 with extensive type and 4 with limited type).
Infectious Complications
All but 1 patient experienced at least 1 episode of infec-
tious complications after CBT (Table 2). The most common
infective pathogen was viruses, including CMV infection,
followed by bacteria and fungus. Four cases of infectious
complications were fatal (2 with bacteremia and 2 with
encephalitis). All of these patients had grade II-IV acute
GVHD (1 with grade II, 1 with grade III, and 2 with grade IV)
and were receiving systemic glucocorticoid therapy when
infectious complications developed.
NRM, Relapse, and Survival
At a median follow-up of 46.2 months (range, 31.0-65.8
months), 16 patients were alive. Causes of death in the other
17 patients included relapse and complications associated
with treatment of relapse after transplantation (12 patients),
infectious complications (4 patients), and graft failure
(1 patient). The cumulative incidence of NRMwas 9% (95% CI,
2%-22%) at 100 days post-HSCT and 15% (95% CI, 5%-30%) at 1
year post-HSCT (Figure 1A). The cumulative incidence of
NRM at 3 years post-HSCT did not differ signiﬁcantly
between standard-risk and high-risk patients (25% versus
10%; P ¼ .254). In 14 patients, disease relapse or progression
occurred at a median of 9 months (range, 0.9-23.0 months)
post-HSCT. The 3-year relapse rate was 42% (95% CI,
25%-59%) (Figure 1B). OS was 51% (95% CI, 34%-68%), and DFS
was 42% (95% CI, 26%-59%) (Figure 1C). The 16 patients who
were alive without disease remained in good condition, with
an Eastern Cooperative Oncology Group performance statusof 0 (n ¼ 13) or 1 (n ¼ 3). Two of the 3 patients who expe-
rienced primary or secondary graft failure and 4 of 14
patients who experienced disease relapse or progression
subsequently underwent a second allogeneic HSCT. At the
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disease at 23 months and 62 months after the second HSCT.
As the possible factors affecting the rates of disease
relapse, NRM, OS, and DFS, the following variables were
analyzed: patient age (<40 years versus 40 years) and sex,
risk categories based on disease status at transplantation
(standard risk versus high risk), HLA disparity (4/6 versus 5/6
and full match), nucleated cell dose of cord blood graft
(<2.60  107/kg versus 2.60  107/kg), and development of
acute GVHD (none or grade I versus grade II-IV). The devel-
opment of grade II-IV acute GVHD had a negative impact on
NRM (1-year NRM, 27% [95% CI, 8%-51%] versus 0%; P < .05);
however, none of other variables, including patient age, had
a signiﬁcant impact on NRM, disease relapse, OS, and DFS.
DISCUSSION
The results of this prospective multicenter study
demonstrate that single-unit CBT following myeloablative
conditioning can provide favorable survival with low NRM in
adult patients with high-risk hematologic malignancies. Our
study is unique in that all patients received uniform condi-
tioning, GVHD prophylaxis, and other supportive care. All of
the CBT procedures applied in this study were identical to
those reported by the IMSUT. In the IMSUT reports, the
outcome of CBT was superior to that of allogeneic BMT or
PBSCT from related and unrelated donors, which provided
a notably favorable outcome compared with other studies
[7,8]. Given the nature of the retrospective single-center
study, we deemed it necessary to conﬁrm the reproduc-
ibility of the results, and consequently planned and con-
ducted a prospective multicenter study to evaluate the safety
and efﬁcacy of the IMSUT transplantation procedures. Of
note, our study enrolled patients with high-risk hematologic
malignancies regardless of disease status at transplantation,
and indeed half of the patients enrolled were not in remis-
sion at the time of transplantation. Despite our use of such
a high-risk cohort, the primary endpoint of 1-year NRM was
15%, which was comparable with the 9% reported by
IMSUT and lower than those of other studies (30%w60%)
[4-6,13-15]. The primary cause of NRM in the present study
was infectious complications occurring after engraftment. All
of those infectious complications occurred in patients who
developed grade II-IV acute GVHD, and the sole factor
signiﬁcantly associated with the incidence of NRMwas grade
II-IV acute GVHD. Thus, to further reduce NRM, the optimal
management of infectious complications should be explored,
particularly in patients developing acute GVHD after CBT.
Disease relapse greatly interferes with the success of
allogeneic HSCT, especially in patients with chemorefractory
hematologic malignancies, and the intensity of conditioning
plays a crucial role. Although TBI plus CY (TBI-CY) remains
the most common myeloablative conditioning regimen for
allogeneic HSCT, further intensiﬁcation of conditioning by
administering additional antileukemic agents has been
attempted in an effort to reduce disease relapse. Although
this further intensiﬁcation can lead to more effective disease
control, the beneﬁt is generally offset by the higher rates of
NRM, and thus the effect of this approach on survival
remains controversial [16]. Cytarabine has been extensively
investigated as an additional agent in this setting, but this
drug is also associated with signiﬁcant toxicity [17-22].
However, in a recent study we found favorable outcomes
with low NRM with the use of TBI-CY plus cytarabine as
conditioning in patients with ALL [9]. Based on these ﬁndings
and the fact that the IMSUT protocol uses mainly TBI-CY pluscytarabine as conditioning for CBT [7,8], we followed the
same regimen. In addition, we combined cytarabine with
G-CSF infusion in patients with myeloid malignancies, based
on the hypothesis that G-CSF increases the susceptibility of
myeloid leukemic cells to cytarabine, thereby contributing to
decreased relapse rate [23-30]. In the setting of allogeneic
BMT and PBSCT, favorable outcomes of the conditioning
consisting of TBI and G-CSF with cytarabine in patients with
AML and advanced MDS have been reported [31-34]. In the
present study, despite the high-risk features of the disease,
approximately half of the patients achieved long-term DFS
with this unique intensiﬁed myeloablative conditioning
because of the low NRM and disease relapse, as expected,
which seemed more favorable than the results of previous
studies [5,14]. These results suggest that the myeloablative
conditioning regimen used in the present study is safe and
highly effective in eradicating leukemic cells even in patients
with high-risk leukemia. However, the outcomes of our
study patients seem inferior to those reported by IMSUT in
terms of disease relapse and survival. The major difference is
in the incidence of disease relapse, which was higher in the
present study (40% versus 16%w17%) and consequently had
an effect on DFS (42% versus 70%w74%). The most plausible
explanation for this difference is the differing study designs
(prospective multicenter versus retrospective single-center).
Another possible explanationmay be related to demographic
differences in the patient cohorts. The standard variables,
such as age and disease status at transplantation, seemed
similar in the 2 studies. However, BMT from unrelated
donors takes priority over CBT in clinical practice in all of the
institutions participating in the present study. Thus, it is
possible that high-risk patients, particularly those with
diseases in CR, might be selectively enrolled into the present
study based on the inclusion criteria deﬁning the require-
ment of immediate HSCT based on disease features at the
discretion of each treating physician. Disease status at
transplantation cannot precisely reﬂect the risk of such
features of the disease and could have signiﬁcantly affected
the outcome.
Along with conditioning, GVHD prophylaxis plays an
important role in the outcomes of allogeneic HSCT. However,
a standard GVHD prophylaxis regimen for CBT has yet to be
established, and GVHD prophylaxis varies widely among
previous studies, variously consisting of CsA or tacrolimus
alone or in combination with MTX, glucocorticoids, myco-
fenolate mofetil (MMF), and/or antithymocyte globulin
[2-6,13-15,35]. To avoid the toxicity and negative effects of
MTX on hematopoietic reconstitution, several studies have
applied noneMTX-containing GVHD prophylaxis. In
contrast, CsA in combination with short-term MTX, which
remains a common GVHD prophylaxis regimen in allogeneic
HSCTs other than CBT, was used in the present study
precisely according to the IMSUT protocol. Leucovorin was
routinely given to ameliorate the toxicity of MTX. In addition,
CsA was given over 10 hours at a dose of 3 mg/kg/day, with
the dose adjusted only when the CsA trough level was
<100 ng/mL or adverse events associated with CsA devel-
oped. With this relatively unique regimen, neutrophil
engraftment was obtained at a median of 26 days after CBT,
which is comparable with those in previous studies. The
incidence of grade II-IV acute GVHD of 48% is identical to that
reported by IMSUT (44%w52%) [7,8]. Of note, however, acute
GVHD was manageable without systemic glucocorticoid
administration in approximately 60% of patients with grade
II acute GVHD, suggesting that the incidence of clinically
T. Mori et al. / Biol Blood Marrow Transplant 19 (2013) 486e491490signiﬁcant acute GVHD requiring systemic glucocorticoid
therapy was actually lower with this prophylactic regimen.
In addition, the development of acute GVHD requiring
systemic glucocorticoid therapy was associated with NRM
due to fatal infectious complications. Therefore, further
investigations should focus on the more effective GVHD
prophylaxis, although the balance between the immuno-
suppressive effect and graft-versus-tumor effect is also
important. In this setting, less-toxic GVHD prophylaxis using
MMF instead of MTX could be a good option, because it has
a potential to allow faster engraftment and could decrease
the risk of infectious complications.
Secondary graft failure due to graft rejection was
observed in 1 patient, who was rescued by the second CBT
and alive at 26 months after the second CBT. Other compli-
cations interfering with survival and quality of life, such as
severe chronic GVHD and secondarymalignancies, were seen
in no patients during the follow-up period. All surviving
patients were in good clinical condition without disease
recurrence. These results demonstrate the long-term safety
and tolerability of these CBT procedures despite the highly
intense conditioning.
Two major limitations of the present study are the small
number of patients evaluated and the heterogeneous disease
background in these patients, including the types of disease,
high-risk features, and disease status at transplantation.
However, the study’s primary endpoint was to evaluate
1-year NRM with respect to safety of the transplantation
procedures. Thus, we believe that safety of the procedures
can be conﬁrmed even with our relatively small, heteroge-
neous cohort.
We conclude that the transplantation methods used in
the present study, including intensiﬁed myeloablative
conditioning, CsA with MTX as GVHD prophylaxis, and other
supportive care measures, can provide low NRM and high
survival rates in patients undergoing single-unit CBT for
hematologic malignancies and could possibly become
a standard treatment. However, because of the limited
number of patients and high incidence of life-threatening
infectious complications associated with GVHD, a larger-
scale study with some modiﬁcations to GVHD prophylaxis
is needed to establish the optimal CBT techniques.
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